AGREEMENT AND PLAN OF MERGER by and among NANTKWEST, INC., NECTARINE MERGER SUB, INC. and IMMUNITYBIO, INC. Dated as of December 21, 2020Merger Agreement • December 21st, 2020 • Cambridge Equities, LP • Biological products, (no disgnostic substances) • Delaware
This AGREEMENT AND PLAN OF MERGER, dated as of December 21, 2020 (this “Agreement”), is entered into by and among ImmunityBio, Inc., a Delaware corporation (the “Company”), NantKwest, Inc., a Delaware corporation (“Parent”), and Nectarine Merger Sub, Inc., a Delaware corporation and a wholly owned Subsidiary of Parent (“Merger Sub” and, together with the Company and Parent, the “Parties” and each, a “Party”).
VOTING AGREEMENTVoting Agreement • December 21st, 2020 • Cambridge Equities, LP • Biological products, (no disgnostic substances) • Delaware
This VOTING AGREEMENT (this “Agreement”), dated as of December 21, 2020, is by and between ImmunityBio, Inc., a Delaware corporation (the “Company”), NantKwest, Inc., a Delaware corporation (“Parent”), and the Persons set forth on Schedule A (the “Parent Significant Stockholders”).
OPTION AGREEMENTOption Agreement • October 23rd, 2015 • Cambridge Equities, LP • Biological products, (no disgnostic substances) • California
This OPTION AGREEMENT (this “Agreement”) is made as of October 13, 2015 by and between Cambridge Equities, LP (“Cambridge”) and Sorrento Therapeutics, Inc. (“Sorrento”).
June 30, 2016 Sorrento Therapeutics, Inc.Shareholder Agreement • July 11th, 2016 • Cambridge Equities, LP • Biological products, (no disgnostic substances) • California
JOINT FILING AGREEMENTJoint Filing Agreement • August 31st, 2015 • Cambridge Equities, LP • Biological products, (no disgnostic substances)
This Joint Filing Agreement may be executed in one or more counterparts, each of which shall be deemed to be an original instrument, but all of such counterparts together shall constitute but one agreement.
JOINT FILING AGREEMENTJoint Filing Agreement • September 21st, 2023 • Cambridge Equities, LP • Biological products, (no disgnostic substances)
This Joint Filing Agreement may be executed in one or more counterparts, each of which shall be deemed to be an original instrument, but all of such counterparts together shall constitute but one agreement.
STOCK TRANSFER AGREEMENTStock Transfer Agreement • February 23rd, 2024 • Cambridge Equities, LP • Electric services
THIS STOCK TRANSFER AGREEMENT (this “Agreement”) is made and entered into as of January 23, 2024, by and between Idealab Holdings, LLC (“ILH”) and Cambridge Equities, LP (“CELP”).
JOINT FILING AGREEMENTJoint Filing Agreement • February 23rd, 2024 • Cambridge Equities, LP • Electric services
This Joint Filing Agreement may be executed in one or more counterparts, each of which shall be deemed to be an original instrument, but all of such counterparts together shall constitute but one agreement.
JOINT FILING AGREEMENTJoint Filing Agreement • July 11th, 2016 • Cambridge Equities, LP • Biological products, (no disgnostic substances)
This Joint Filing Agreement may be executed in one or more counterparts, each of which shall be deemed to be an original instrument, but all of such counterparts together shall constitute but one agreement.
JOINT FILING AGREEMENTJoint Filing Agreement • December 7th, 2022 • Cambridge Equities, LP • Biological products, (no disgnostic substances)
This Joint Filing Agreement may be executed in one or more counterparts, each of which shall be deemed to be an original instrument, but all of such counterparts together shall constitute but one agreement.
